Stock Financial Ratios, Dividends, Split History

TPH / Tri Pointe Homes, Inc. financial ratios include Market Cap, Enterprise Value, Book Value, Quick Ratio, Current Ratio, NCAV, EBITDA, Profit Margin, Operating Margin, Return on Invested Capital (ROIC), Return on Assets (ROA), Return on Equity (ROE), Piotroski F-Score, Altman Z-Score, Beneish M Score and Kaplan-Zingales KZ-Index.

Valuation Metrics
Market Cap ($M)2,524.95
Enterprise Value ($M)2,200.95
Book Value ($M)1,963.64
Book Value / Share12.93
Price / Book1.33
NCAV / Sharen/a
Price / NCAVn/a
Share Statistics
Weighted Average Number Of Diluted Shares Outstanding 155,085,366
Common Stock Shares Outstanding 151,162,999
Preferred Stock Shares Outstanding 0
Weighted Average Number Of Shares Outstanding Basic 154,134,411
Common Shares Outstanding 151,212,457
Scoring Models
Piotroski F-Score5.00
Altman Z ScoreN/A
Beneish M ScoreN/A
Management Effectiveness (mra)
Return on Invested Capital (ROIC)0.06
Return on Assets (ROA)0.05
Return on Equity (ROE)0.10
Balance Sheet (mrq) ($M)
Quick Ration/a
Current Ration/a
Income Statement (mra) ($M)
Home Building Revenue2,732,299,000.00
Real Estate Revenue Net2,808,901,000.00
Financial Services Revenue1,371,000.00
Other Real Estate Revenue2,333,000.00
Operating Income343.63
Net Income187.55
Earnings Per Share Diluted1.21
Earnings Per Share Basic1.21
Cash Flow Statement (mra) ($M)
Cash From Operations101.67
Cash from Investing-3.58
Cash from Financing-3.58
Identifiers and Descriptors
Central Index Key (CIK)1561680
Related CUSIPS
87265H909 87265H959

Split History

Stock splits are used by Tri Pointe Homes, Inc. to keep share prices within reasonable numbers to encourage investment. If the share price of a security gets too high, a company can perform a stock split by issuing all shareholders an extra share, thereby halving the price of an individual share. If the share price gets too low, companies can do reverse splits. This is common when share prices drop below $1.00 and company's become in danger of being delisted. However, because of the cost, stock splits are not a normal business occurrence.

Coming soon

Related Articles

HRTX : Heron Therapeutics Analysis and Research Report

2018-05-25 - Asif

Overview Heron is a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments that address some of the most important unmet patient needs. Heron Therapeutics is developing novel, patient-focused solutions that apply its innovative science and technologies to already approved pharmacological agents for patients suffering from cancer or pain. On August 9, 2016, its first commercial product, SUSTOL, was approved by the FDA. The company developed SUSTOL for the prevention of chemotherapy-induced nausea and vomiting (“CINV”). SUSTOL is indicated, in combination with other antiemetics, in adults for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic chemotherapy (“MEC”) or anthracycline and cyclophosphamide (“AC”) combination chemotherapy regimens. The company commenced commercial sales of SUSTOL in the U.S. in October 2016. On November 9, 2017...

ACIA: Acacia Communications Analysis and Research Report

2018-05-25 - Asif

Overview The company's mission is to deliver high-speed coherent optical interconnect products that transform communications networks, relied upon by cloud infrastructure operators and content and communication service providers, through improvements in performance and capacity and reductions in associated costs. By converting optical interconnect technology to a silicon-based technology, a process the company refer to as the siliconization of optical interconnect, the company believe Acacia Communications is leading a disruption that is analogous to the computing industry’s integration of multiple functions into a microprocessor. The company's products include a family of low-power coherent digital signal processor application-specific integrated circuits, or DSP ASICs, and silicon photonic integrated circuits, or silicon PICs, which Acacia Communications has integrated into families of optical interconnect modules with transmission speeds ranging from 100 to 400 gigabits per ...

ANTH: Anthera Pharmaceuticals Analysis and Research Report

2018-05-21 - Asif

Overview Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on advancing the development and commercialization of innovative medicines that benefit patients with unmet medical needs. The company currently have two compounds in development, Sollpura and blisibimod. The company licensed Sollpura from Eli Lilly & Co (“Eli Lilly”) in July 2014. Sollpura is a novel non-porcine investigational Pancreatic Enzyme Replacement Therapy (“PERT”) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (“EPI”), often seen in patients with cystic fibrosis and other conditions. The company licensed blisibimod from Amgen, Inc. (“Amgen”) in December 2007. Blisibimod targets B-cell activating factor, or BAFF, which has been shown to be elevated in a variety of B-cell mediated autoimmune diseases, including Immunoglobulin A nephropathy, or IgA nephropathy. Sollpura The exocrine pancreas is responsible for synthesis and secretion of digestive en...

Related News Stories

TRI Pointe's (TPH) CEO Doug Bauer on Q1 2018 Results - Earnings Call Transcript

2018-04-25 seekingalpha
TRI Pointe Group, Inc. (NYSE:TPH) Q1 2018 Earnings Conference Call April 25, 2018 10:00 AM ET (34-0)

TRI Pointe's (TPH) CEO Doug Bauer on Q4 2017 Results - Earnings Call Transcript

2018-02-20 seekingalpha
TRI Pointe Group, Inc. (NYSE:TPH) Q4 2017 Earnings Conference Call February 20, 2018 10:00 AM ET (2-0)

TRI Pointe Homes 2017 Q4 - Results - Earnings Call Slides

2018-02-20 seekingalpha
The following slide deck was published by TRI Pointe Homes in conjunction with their 2017 Q4 earnings call. (2-0)

Put These 4 High Earnings Yield Stocks in Your Portfolio

2018-01-25 investorplace
There are some key parameters in the world of finance. For instance, in some situations, investors may be baffled whether to invest their money in stocks or bonds. In such cases, carefully selected financial metrics can show the right direction to investors. (9-0)

U.S. New Home Sales Surge in November: Housing Stocks in Focus

2017-12-27 zacks
Last week, the Census Bureau and the Department of Housing and Urban Development jointly announced that sales of new residential houses jumped significantly in November 2017. According to the data, 733,000 new single-family houses were sold in November, 17.5% above the revised rate of 624,000 in October and 26.6% above the year-ago estimate of 579,000. Sales were specifically strong in the West and South which recorded increases of 31. (2-0)

CUSIP: 87265H109